EssilorLuxottica Société Anonyme (ENXTPA:EL) Expands Smart Eyewear, Is It Still 38% Below Fair Value?

EssilorLuxottica Société anonyme (ENXTPA:EL) has pushed deeper into tech-enabled eyewear with Nuance Audio Plus, an FDA-cleared hearing solution embedded in glasses, alongside a fresh wave of AI and audio products with Meta Platforms.

These product launches arrive after a tough stretch for EssilorLuxottica Société anonyme’s investors, with the share price down 45.6% year to date and the 1-year total shareholder return declining 46.4%, while the 5-year total shareholder return is only slightly lower at 0.8%.

Scan how EssilorLuxottica Société anonyme’s smart eyewear story compares with other niche tech plays by reviewing a curated short list of 36 profitable AI stocks that aren't just burning cash.

After a 45.6% slide this year, alongside fresh bets on AI glasses and hearing-ready eyewear, does EssilorLuxottica Société anonyme now offer enough potential upside to justify the hit investors are being asked to stomach?

Most Popular Narrative: 38% Undervalued

EssilorLuxottica Société anonyme last closed at €144.50, while the most widely followed narrative pegs fair value at about €232.61. The gap in expectations is wide and rests heavily on how its tech-heavy eyewear push plays out.

Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.

See why 37 investors see EssilorLuxottica Société anonyme as 38% undervalued.

Result: Fair Value of €232.61 (UNDERVALUED)

Still, EssilorLuxottica Société anonyme faces real pressure if smart eyewear adoption underwhelms, or if inflation and tariffs keep squeezing already sensitive margins.

Find out about the key risks to this EssilorLuxottica Société anonyme narrative.

Another View: What Multiples Say About EssilorLuxottica Société anonyme

EssilorLuxottica Société anonyme screens as undervalued on fair value and future cash flow work, yet the P/E ratio of 26.6x tells a more cautious story. It is above the fair ratio of 22.7x and above the European Medical Equipment average of 25.8x, so anyone buying today is still paying up for quality. If the market drifts closer to that fair ratio, how comfortable are you with the valuation gap you are stepping into?

To see how that premium lines up with other companies using the same yardstick, take a closer look at our valuation breakdown: See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment is split around EssilorLuxottica Société anonyme, and the gap between risks and rewards is not small, so move quickly and test the numbers yourself. To weigh that trade off in a structured way, start with 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond EssilorLuxottica Société anonyme?

If EssilorLuxottica Société anonyme has sharpened your focus on opportunity and risk, do not stop here. The next move that reshapes your portfolio might be sitting in plain sight.

• Target resilient balance sheets and steadier financial profiles by scanning a focused list of solid balance sheet and fundamentals (207 results) that filters out weaker businesses before you even start your research.
• Hunt for mispriced quality and use 184 high quality undervalued stocks to quickly surface stocks where fundamentals and current valuations appear out of sync.
• Prioritize stability and smoother ride potential by reviewing 226 resilient stocks with low risk scores so you are not the last to spot companies with calmer risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com